GetTopicDetailResponse(id=4639263155d, topicName=低級別漿液性卵巢癌, introduction=低級別漿液性卵巢癌, content=null, image=null, comments=1, allHits=1568, url=https://h5.medsci.cn/topic?id=26315, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=103624, tagList=[TagDto(tagId=103624, tagName=低級別漿液性卵巢癌)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2265411, encodeId=69de2265411e0, content=<a href='/topic/show?id=ce9a58694b8' target=_blank style='color:#2F92EE;'>#新輔助內(nèi)分泌治療#</a> <a href='/topic/show?id=4639263155d' target=_blank style='color:#2F92EE;'>#低級別漿液性卵巢癌#</a>, objectTitle=13歲IIIC期低級別漿液性卵巢癌未檢出可靶突變，獲益氟維司群/哌柏西利/亮丙瑞林新型新輔助內(nèi)分泌治療, objectType=article, longId=877718, objectId=d1a58e77188a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-in-his-practice-with-a-digital-tablet-UWZKVBN.jpg, objectUrl=/article/show_article.do?id=d1a58e77188a, replyNumber=0, likeNumber=22, createdTime=2025-05-17, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d1a58e77188a, moduleTitle=13歲IIIC期低級別漿液性卵巢癌未檢出可靶突變，獲益氟維司群/哌柏西利/亮丙瑞林新型新輔助內(nèi)分泌治療, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=d1a58e77188a)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2190224, encodeId=7bb6219022485, content=<a href='/topic/show?id=2ebf1128ef1' target=_blank style='color:#2F92EE;'>#MAPK通路#</a> <a href='/topic/show?id=4639263155d' target=_blank style='color:#2F92EE;'>#低級別漿液性卵巢癌#</a> <a href='/topic/show?id=4919109922db' target=_blank style='color:#2F92EE;'>#比美替尼#</a>, objectTitle=CCR：復發(fā)性低級別漿液性卵巢癌攜帶MAPK通路變異，對比美替尼和化療均有較高的緩解率, objectType=article, longId=814879, objectId=17bd8148e924, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-writing-a-medical-recipe-P8LEKCP.jpg, objectUrl=/article/show_article.do?id=17bd8148e924, replyNumber=0, likeNumber=78, createdTime=2024-02-29, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=17bd8148e924, moduleTitle=CCR：復發(fā)性低級別漿液性卵巢癌攜帶MAPK通路變異，對比美替尼和化療均有較高的緩解率, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=17bd8148e924)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=880516, encodeId=54ab88051603, content=<a href='/topic/show?id=4639263155d' target=_blank style='color:#2F92EE;'>#低級別漿液性卵巢癌#</a>, objectTitle= J Clin Oncol：MEK1/2抑制劑Binimetinib治療低級別漿液性卵巢癌的療效, objectType=article, longId=199949, objectId=9c171999498a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020826/1598435802962_2110107.PNG, objectUrl=/article/show_article.do?id=9c171999498a, replyNumber=0, likeNumber=150, createdTime=2020-08-29, rootId=0, userName=qinqiyun, userId=74c72110107, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c171999498a, moduleTitle= J Clin Oncol：MEK1/2抑制劑Binimetinib治療低級別漿液性卵巢癌的療效, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=9c171999498a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
